在缺血和再输液过程中准可溶性关利基环酶
Eric H Mace1, Melissa J Kimlinger2, Frederic T Billings3
1Department of Surgery, Vanderbilt University Medical Center, Medical Center North, Suite CCC-4312, 1161 21st Avenue South, Nashville, TN 37232-2730, USA.
Cells
|July 29, 2023
概括
可溶性瓜尼利基环酶 (sGC) 刺激剂和激活剂在减少因缺血和再注射 (IR) 损伤造成的器官损伤方面表现有前途. 临床前研究表明,这些疗法可以改善血管扩张并减少多个器官的损伤,因此需要进一步的临床研究.
科学领域:
- 心血管研究研究心血管研究
- 腎臟病學 (nephrology) 是一種醫學專業.
- 肝病学 肝病学是一种肝病学.
- 神经学 神经学
- 肺部病理学 肺部病理学
背景情况:
- 缺血和再注射 (IR) 损伤是导致器官损伤和疾病的重要因素.
- 有效的治疗方法来减轻IR损伤是有限的.
- 氧化 (NO) 信号是红外伤害的潜在治疗目标.
研究的目的:
- 审查药理溶性瓜尼利环酶 (sGC) 刺激剂和激活剂在减轻IR损伤方面的治疗潜力.
- 在IR的背景下,探索sGC调制影响血管扩张,内皮完整性和炎症的机制.
- 在急性IR条件下评估sGC向治疗的临床前和临床证据.
主要方法:
- 在各种IR损伤模型中对sGC刺激剂和激活剂进行临床前研究的审查.
- 分析涉及NO-sGC-循环-GMP信号的分子通路.
- 对慢性和急性疾病中sGC调节器的临床试验数据的检查.
主要成果:
- 临床前研究表明,SGC刺激剂和激活剂都能在IR后减少心脏,脑,,肺和肝损伤.
- 这些好处归因于加强血管扩张,改善 perfusion 调节和减少氧化应激.
- 虽然sGC刺激剂在临床上已被批准用于慢性疾病,但sGC激活剂由于低血压等不良影响而面临临临床试验终止.
结论:
- 药理学调制sGC代表了治疗IR损伤的有希望的策略.
- 考虑到不同的安全性,对急性IR条件的sGC刺激剂和激活剂进行进一步的临床研究是有必要的.
- 了解精确的机制和优化治疗策略对于将这些发现转化为临床实践至关重要.
更多相关视频
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
12.7K
11:07A Murine Model of Myocardial Ischemia-reperfusion Injury through Ligation of the Left Anterior Descending Artery
Published on: April 10, 2014
39.7K
相关概念视频
01:09GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K